HIV/AIDS Therapy
Mycophenolate mofetil and HAART delays viral load rebound in HIV infection
Published in Anti-Infectives Week, September 20th, 2004
"The main goal of this study was to assess the role of mycophenolate mofetil (MMF) during interruption of highly active antiretroviral therapy (HAART).
"Seventeen patients with early-stage chronic HIV type 1 infection were treated with highly active antiretroviral therapy (HAART) for 12 months. They were then randomized (day 0) to receive MMF (HAART-MMF group, n=9) or to continue the regimen (HAART group, n=6) for 120 additional days.
"At day 120 in the HAART-MMF group, HAART was discontinued, and MMF administration was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
Source: Anti-Infectives Week (2004-09-20)
More Articles from Anti-Infectives Week
- Anti-Infectives
Effect of magnesium glutamate on aqueous penicillin G stability determined - Anti-Infectives
Quality control guidelines for investigational cephalosporin presented - Aspergillus Terreus
Voriconazole may be better than a polyene for Aspergillus terreus infection - Bacterial Infection
Age/primary infection foci differs in invasive/noninvasive group A streptococci - Hemorrhagic Fever
Ribavarin therapy effective against Crimean-Congo hemorrhagic fever - Antiretroviral Therapy
HAART improves course of hepatitis C virus infection in HIV coinfected patients - More from this issue of Anti-Infectives Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
